Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | -900.00K | 0.00 | -3.49M | -8.96M | -4.45M | -1.39M |
EBITDA | -120.43M | -113.39M | -114.37M | -90.89M | -67.58M | -41.95M |
Net Income | -118.60M | -116.91M | -117.86M | -90.77M | -68.78M | -43.34M |
Balance Sheet | ||||||
Total Assets | 109.31M | 142.89M | 198.13M | 299.37M | 242.59M | 75.91M |
Cash, Cash Equivalents and Short-Term Investments | 60.03M | 91.93M | 137.18M | 230.25M | 207.47M | 48.54M |
Total Debt | 30.78M | 31.83M | 35.66M | 38.91M | 18.01M | 18.29M |
Total Liabilities | 43.24M | 46.23M | 47.40M | 48.76M | 26.33M | 27.64M |
Stockholders Equity | 66.07M | 96.66M | 150.72M | 250.61M | 216.26M | 48.27M |
Cash Flow | ||||||
Free Cash Flow | -100.61M | -99.89M | -101.36M | -93.61M | -73.04M | -40.45M |
Operating Cash Flow | -100.26M | -99.66M | -100.29M | -85.14M | -69.14M | -36.29M |
Investing Cash Flow | 52.65M | 96.86M | 71.01M | -94.09M | -91.65M | -4.16M |
Financing Cash Flow | 52.69M | 53.39M | 2.94M | 117.14M | 232.91M | 82.53M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
49 Neutral | $87.58M | ― | 149.62% | ― | -18.22% | 44.67% | |
47 Neutral | $107.22M | ― | -45.55% | ― | 98.56% | 37.97% | |
47 Neutral | $57.64M | ― | -116.63% | ― | -100.00% | 24.59% | |
46 Neutral | $89.22M | ― | -59.45% | ― | ― | 48.92% | |
46 Neutral | C$194.85M | -4.28 | -8.56% | 2.84% | 13.52% | -1.74% | |
37 Underperform | $71.82M | ― | -63.22% | ― | -100.00% | -26.44% | |
33 Underperform | $181.19M | ― | -125.43% | ― | ― | 2.98% |
On March 31, 2025, Eyal C. Attar, M.D., announced his resignation as Chief Medical Officer of Vor Biopharma Inc., effective April 18, 2025, to pursue a new opportunity. Vor Biopharma plans to enter into a consulting agreement with Dr. Attar for transition services, acknowledging his contributions to the company.
On February 3, 2025, Vor Biopharma’s board approved a stock option repricing to reduce the exercise price of certain options to $1.34 per share, impacting approximately 6.76 million shares. This move aims to motivate and retain employees while avoiding stock dilution or additional cash outlays, with a retention period set until February 3, 2026 or earlier under specific conditions.